^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

KROS-201

i
Other names: KROS-201, activated T cells
Associations
Company:
Kairos Pharma
Drug class:
T-cell stimulant
Associations
5ms
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma (clinicaltrials.gov)
P1, N=10, Not yet recruiting, Jeremy Rudnick, M.D | Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2023 --> Dec 2025
Trial completion date • Trial primary completion date
|
KROS-201
over2years
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • IL13RA2 (Interleukin 13 Receptor Subunit Alpha 2)
|
CD133 expression • HLA-A2 positive
|
KROS-201